






This site was inspired by my Mom’s autoimmune dementia.
It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.
The site is dedicated to all those preserving the dignity of the community of people living with dementia.
Peter Berger, Editor
Share this page To

Europe originally said Lecanemab (Brand-name Leqembi) was too risky to approve. Now they are recommending marketing it. Why the change of heart?

People may not have easy access to sophisticated, expensive dementia tests. A simple test from Einstein Medicine uses a stopwatch and a few questions to determine one’s risk of dementia. The potential payoff could be tremendous for individuals, their families and society.

Researchers find education and intellectual stimulation appear to activate a genetic program in the brain that promotes resistance to cognitive decline. Find out more.

The 2 newest Alzheimer’s drugs, Leqembi (lecanemab) and Kisunla (donanemab) show promise, but many questions remain. Here are the three next ones.
This site was inspired by my Mom’s autoimmune dementia.
It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.
The site is dedicated to all those preserving the dignity of the community of people living with dementia.
Peter Berger, Editor
Visit Alzheimer's Weekly On